JPWO2021201239A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021201239A5 JPWO2021201239A5 JP2022559750A JP2022559750A JPWO2021201239A5 JP WO2021201239 A5 JPWO2021201239 A5 JP WO2021201239A5 JP 2022559750 A JP2022559750 A JP 2022559750A JP 2022559750 A JP2022559750 A JP 2022559750A JP WO2021201239 A5 JPWO2021201239 A5 JP WO2021201239A5
- Authority
- JP
- Japan
- Prior art keywords
- aripiprazole
- formulation
- patient
- oral
- single dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025137577A JP2025176037A (ja) | 2020-04-01 | 2025-08-21 | アリピプラゾール治療の投薬開始のための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003544P | 2020-04-01 | 2020-04-01 | |
| US63/003,544 | 2020-04-01 | ||
| PCT/JP2021/014194 WO2021201239A1 (en) | 2020-04-01 | 2021-04-01 | Methods for dose initiation of aripiprazole treatments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025137577A Division JP2025176037A (ja) | 2020-04-01 | 2025-08-21 | アリピプラゾール治療の投薬開始のための方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023520004A JP2023520004A (ja) | 2023-05-15 |
| JPWO2021201239A5 true JPWO2021201239A5 (https=) | 2025-05-21 |
| JP2023520004A5 JP2023520004A5 (https=) | 2025-05-21 |
| JP7733000B2 JP7733000B2 (ja) | 2025-09-02 |
Family
ID=75581573
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559751A Active JP7584535B2 (ja) | 2020-04-01 | 2021-04-01 | アリピプラゾール注射用調製物を投与する方法 |
| JP2022559750A Active JP7733000B2 (ja) | 2020-04-01 | 2021-04-01 | アリピプラゾール治療の投薬開始のための方法 |
| JP2024193628A Pending JP2025020306A (ja) | 2020-04-01 | 2024-11-05 | アリピプラゾール注射用調製物を投与する方法 |
| JP2025137577A Pending JP2025176037A (ja) | 2020-04-01 | 2025-08-21 | アリピプラゾール治療の投薬開始のための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559751A Active JP7584535B2 (ja) | 2020-04-01 | 2021-04-01 | アリピプラゾール注射用調製物を投与する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193628A Pending JP2025020306A (ja) | 2020-04-01 | 2024-11-05 | アリピプラゾール注射用調製物を投与する方法 |
| JP2025137577A Pending JP2025176037A (ja) | 2020-04-01 | 2025-08-21 | アリピプラゾール治療の投薬開始のための方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20220160621A1 (https=) |
| EP (3) | EP4125903B1 (https=) |
| JP (4) | JP7584535B2 (https=) |
| KR (3) | KR102732030B1 (https=) |
| CN (3) | CN115397420A (https=) |
| AU (2) | AU2021245713A1 (https=) |
| BR (2) | BR112022018647A2 (https=) |
| CA (3) | CA3136727A1 (https=) |
| ES (1) | ES2995466T3 (https=) |
| HR (1) | HRP20241574T1 (https=) |
| HU (1) | HUE069157T2 (https=) |
| MX (2) | MX2022012353A (https=) |
| PL (1) | PL4125903T3 (https=) |
| TW (3) | TWI865760B (https=) |
| WO (2) | WO2021201238A1 (https=) |
| ZA (1) | ZA202210633B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| TWI865760B (zh) | 2020-04-01 | 2024-12-11 | 日商大塚製藥股份有限公司 | 阿立哌唑注射用製劑之投予方法 |
| US20250387321A1 (en) | 2023-03-17 | 2025-12-25 | Otsuka Pharmaceutical Co., Ltd. | Methods of dispersing aripiprazole injectable preparations |
| AU2024263986A1 (en) * | 2023-04-26 | 2025-10-09 | Otsuka Pharmaceutical Co., Ltd. | Dose initiation for schizophrenia or bipolar i disorder treatment with aripiprazole |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| ATE411797T2 (de) * | 2003-10-23 | 2008-11-15 | Otsuka Pharma Co Ltd | Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren |
| MX2009014115A (es) | 2007-06-25 | 2010-04-21 | Otsuka Pharma Co Ltd | Microesferas que tienen estructura de nucleo/corteza. |
| JOP20200109A1 (ar) * | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| US10525057B2 (en) | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
| JP2020520380A (ja) * | 2017-05-16 | 2020-07-09 | ボウ リバー エルエルシー | 処置法 |
| EP3761983A1 (en) * | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN108498456B (zh) | 2018-05-16 | 2021-01-01 | 丽珠医药集团股份有限公司 | 一种阿立哌唑缓释微球及其制备方法 |
| CN110327296B (zh) | 2019-08-06 | 2021-10-22 | 深圳市泛谷药业股份有限公司 | 一种阿立哌唑长效注射制剂及其制备方法 |
| TWI865760B (zh) | 2020-04-01 | 2024-12-11 | 日商大塚製藥股份有限公司 | 阿立哌唑注射用製劑之投予方法 |
-
2021
- 2021-04-01 TW TW110112186A patent/TWI865760B/zh active
- 2021-04-01 JP JP2022559751A patent/JP7584535B2/ja active Active
- 2021-04-01 WO PCT/JP2021/014192 patent/WO2021201238A1/en not_active Ceased
- 2021-04-01 US US17/594,292 patent/US20220160621A1/en not_active Abandoned
- 2021-04-01 CN CN202180025911.8A patent/CN115397420A/zh active Pending
- 2021-04-01 CN CN202180026022.3A patent/CN115379842A/zh active Pending
- 2021-04-01 CA CA3136727A patent/CA3136727A1/en active Pending
- 2021-04-01 PL PL21720012.0T patent/PL4125903T3/pl unknown
- 2021-04-01 EP EP21720012.0A patent/EP4125903B1/en active Active
- 2021-04-01 BR BR112022018647A patent/BR112022018647A2/pt unknown
- 2021-04-01 ES ES21720012T patent/ES2995466T3/es active Active
- 2021-04-01 TW TW110112185A patent/TWI906279B/zh active
- 2021-04-01 KR KR1020227037401A patent/KR102732030B1/ko active Active
- 2021-04-01 AU AU2021245713A patent/AU2021245713A1/en active Pending
- 2021-04-01 KR KR1020227037400A patent/KR20220161402A/ko active Pending
- 2021-04-01 MX MX2022012353A patent/MX2022012353A/es unknown
- 2021-04-01 TW TW113142852A patent/TW202523329A/zh unknown
- 2021-04-01 US US17/907,583 patent/US20230129919A1/en not_active Abandoned
- 2021-04-01 CA CA3163321A patent/CA3163321C/en active Active
- 2021-04-01 CA CA3212191A patent/CA3212191A1/en active Pending
- 2021-04-01 AU AU2021248212A patent/AU2021248212A1/en active Pending
- 2021-04-01 CN CN202411916296.1A patent/CN119792290A/zh active Pending
- 2021-04-01 HR HRP20241574TT patent/HRP20241574T1/hr unknown
- 2021-04-01 KR KR1020247038040A patent/KR20240165486A/ko active Pending
- 2021-04-01 EP EP24205231.4A patent/EP4467194A3/en active Pending
- 2021-04-01 EP EP21720011.2A patent/EP3941470A1/en active Pending
- 2021-04-01 JP JP2022559750A patent/JP7733000B2/ja active Active
- 2021-04-01 MX MX2022012354A patent/MX2022012354A/es unknown
- 2021-04-01 BR BR112022018721A patent/BR112022018721A2/pt unknown
- 2021-04-01 WO PCT/JP2021/014194 patent/WO2021201239A1/en not_active Ceased
- 2021-04-01 HU HUE21720012A patent/HUE069157T2/hu unknown
-
2022
- 2022-09-26 ZA ZA2022/10633A patent/ZA202210633B/en unknown
-
2023
- 2023-03-15 US US18/184,135 patent/US20230225962A1/en not_active Abandoned
-
2024
- 2024-06-03 US US18/732,392 patent/US20240374506A1/en active Pending
- 2024-11-05 JP JP2024193628A patent/JP2025020306A/ja active Pending
-
2025
- 2025-08-21 JP JP2025137577A patent/JP2025176037A/ja active Pending
- 2025-10-08 US US19/352,541 patent/US20260034053A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marchetti et al. | Efficacy and safety of oral ketamine for the relief of intractable chronic pain: a retrospective 5‐year study of 51 patients | |
| Wedemeyer et al. | Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection | |
| JP2019196370A5 (https=) | ||
| JP2016204396A5 (https=) | ||
| JP2013509435A5 (https=) | ||
| JP2005520778A5 (https=) | ||
| NO975334L (no) | Anvendelse av flavanolignaner for fremstilling av medikamenter med antiproliferativ aktivitet i uterus, ovarium og bryst | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| HRP20241574T1 (hr) | Metode za početak doziranja liječenja aripiprazolom | |
| JPH05500973A (ja) | 化学的組成物 | |
| JP2018510894A5 (https=) | ||
| KR20120023754A (ko) | Ａｖｅ８０６２ 및 소라페닙을 포함하는 항종양 조합물 | |
| JPWO2021201239A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| JP2021502347A5 (https=) | ||
| JP2023109829A5 (https=) | ||
| JP2022035920A5 (https=) | ||
| JP2007501806A5 (https=) | ||
| JP2021535163A5 (https=) | ||
| Vadlamudi et al. | Schedule-dependent therapeutic synergism for L-asparaginase and methotrexate in leukemic (L5178Y) mice | |
| MX2023005431A (es) | Composicion farmaceutica, formulacion farmaceutica combinada, y kit de formulacion combinada para la prevencion o el tratamiento de la hepatitis b cronica, cada uno que comprende, como ingrediente activo, un agente antiviral oral y una vacuna terapeutica que incluye un lipopeptido y un adyuvante de poli(i:c). | |
| Dotevall et al. | Controlled clinical trial of mepiprazole in irritable bowel syndrome | |
| JP2005529152A5 (https=) | ||
| Moodley | Local anaesthetics in dentistry-Part 2: Choice of local anaesthetic agent | |
| JP2005508323A5 (https=) |